Molbio Diagnostics Limited launched its ₹939.70 crore Initial Public Offering (IPO) on August 10, 2026. The Goa-based molecular diagnostics company is best known for its proprietary Truenat platform, a portable, battery-operated real-time PCR testing system designed to deliver molecular diagnostic results at the point of care, including in remote and resource-constrained settings.
Backed by investors such as Temasek and Motilal Oswal Private Equity, Molbio Diagnostics combines diagnostic hardware with recurring consumable test-kit sales across diseases including tuberculosis, hepatitis, dengue and COVID-19. The company has also built an international presence across more than 90 countries. This Molbio Diagnostics IPO Analysis examines the IPO structure, business model, Truenat platform, financial performance, use of proceeds, valuation, peer comparison, risks and long-term investment considerations.
Looking beyond IPOs? Explore Finology 30.
Table of Contents
- Molbio Diagnostics IPO 2026: Key Highlights
- IPO Structure: Fresh Issue and Offer for Sale
- Anchor Investor Allocation and Public Issue Structure
- Where Will Molbio Diagnostics Use the IPO Proceeds?
- Molbio Diagnostics Business Model and Revenue Strategy
- Understanding the Truenat Diagnostic Platform
- Molbio Diagnostics Manufacturing and Global Presence
- Competitive Strengths and Entry Barriers
- Molbio Diagnostics Financial Performance
- Molbio Diagnostics IPO Valuation
- Molbio Diagnostics IPO Peer Comparison
- Key Risks in Molbio Diagnostics IPO
- Grey Market Premium and Listing Gain Expectations
- Molbio Diagnostics IPO Review: Listing Gains vs Long-Term Investment
- Molbio Diagnostics IPO: What Investors Should Track After Listing
- Molbio Diagnostics IPO: Pros and Cons
- Final Verdict on Molbio Diagnostics IPO
- Molbio Diagnostics IPO FAQs
The Molbio Diagnostics IPO is a ₹939.70 crore mainboard issue comprising a ₹200 crore fresh issue and a ₹739.70 crore Offer for Sale (OFS). The IPO opened for subscription on August 10, 2026 and is scheduled to close on August 12, 2026.
The company has priced the issue in the range of ₹768 to ₹807 per equity share. At the upper end of the price band, Molbio Diagnostics is valued at approximately ₹9,300 crore in terms of market capitalisation.
The IPO provides investors exposure to the point-of-care molecular diagnostics segment through a company that has developed proprietary diagnostic technology, established manufacturing capabilities and a presence across more than 90 countries.
Molbio Diagnostics IPO Details
| IPO Parameter |
Details |
| IPO size |
Approximately ₹939.70 crore |
| IPO type |
Mainboard IPO |
| IPO bidding dates |
August 10 to August 12, 2026 |
| Price band |
₹768 to ₹807 per share |
| Face value |
₹1 per share |
| Fresh issue |
₹200 crore |
| Offer for Sale |
₹739.70 crore |
| Lot size |
18 shares |
| Minimum investment |
₹14,526 at ₹807 |
| Listing exchanges |
BSE and NSE |
| Tentative allotment |
August 13, 2026 |
| Tentative listing |
August 17, 2026 |
| Registrar |
KFin Technologies Limited |
/content-assets/a24ccef99ced40b4ab9b7603db42da85.png)
Get all the latest updates on the Molbio Diagnostics IPO, including its price band, issue size, lot size, IPO dates, and listing details.
Molbio Diagnostics IPO Date and Important Schedule
The Molbio Diagnostics IPO Date is August 10, 2026, when bidding opened for investors. The subscription window will remain open until August 12, 2026.
The tentative IPO timeline is as follows:
-
IPO opens: August 10, 2026
-
IPO closes: August 12, 2026
-
Basis of allotment: August 13, 2026
-
Tentative listing: August 17, 2026
The shares are proposed to be listed on both the BSE and NSE.
The issue is being managed by Kotak Mahindra Capital, IIFL Capital, Jefferies and Motilal Oswal. KFin Technologies is acting as the registrar to the issue.
Molbio Diagnostics IPO Price, Lot Size and Investment
The Molbio Diagnostics IPO Price has been fixed within a band of ₹768 to ₹807 per share. Investors can bid at any price within this range, subject to the applicable IPO bidding mechanism.
The lot size is 18 shares. At the upper price band of ₹807, one retail lot requires an investment of:
18 × ₹807 = ₹14,526
Therefore, ₹14,526 is the minimum application amount for a retail investor bidding at the upper price band.
The face value of each equity share is ₹1.
The pricing reflects the premium valuation assigned to Molbio's proprietary molecular diagnostics technology, recurring consumables business and international footprint.
The Molbio Diagnostics IPO consists of two components: a fresh issue and an Offer for Sale.
The ₹200 crore fresh issue will result in new capital being raised by the company. In contrast, the ₹739.70 crore OFS represents shares being sold by existing shareholders.
This distinction is important for investors because the fresh issue brings funds into Molbio Diagnostics for business purposes, while the OFS proceeds primarily go to the selling shareholders.
Fresh Issue vs OFS
| Component |
Amount and Details |
| Fresh issue |
₹200 crore, comprising approximately 24.80 lakh shares |
| Offer for Sale |
₹739.70 crore, comprising approximately 91.66 lakh shares |
| Total issue |
Approximately ₹939.70 crore |
Around 79% of the total IPO size comes through the OFS, while roughly 21% represents fresh capital for the company.
This makes the IPO predominantly an exit or partial monetisation event for existing shareholders rather than a large capital-raising exercise for Molbio itself.
Before the IPO opened for public subscription, Molbio Diagnostics raised ₹281.5 crore from 33 anchor investors at the upper price band of ₹807 per share.
Domestic mutual funds accounted for 67.5% of the anchor book, with participation from 19 mutual funds. The anchor allocation provides an indication of institutional interest ahead of the public issue, although it should not be interpreted as a guarantee of future share performance.
The net public offer is divided among different investor categories.
Category Allocation
-
Qualified Institutional Buyers (QIBs): Up to 75% of the net issue
-
Non-Institutional Investors (NIIs/HNIs): Not less than 15%
-
Retail Individual Investors (RIIs): Not less than 10%
The institutional allocation is particularly relevant for Molbio because the company's business involves specialised technology, international markets and a long-term growth profile that may attract investors with a longer investment horizon.
The company is raising ₹200 crore through the fresh issue. The stated purpose is primarily to support expansion, infrastructure, manufacturing capabilities and research and development rather than repay debt.
Research and Development Infrastructure
Around ₹106 crore is earmarked towards establishing a dedicated research and development facility, a Centre of Excellence and corporate infrastructure.
For a diagnostics company whose competitive positioning depends heavily on proprietary technology, R&D investment is strategically important.
Molecular diagnostics is a technology-intensive segment. Continued investment in product development, assay capabilities and diagnostic platforms can help Molbio expand its addressable market beyond its existing disease portfolio.
Manufacturing Equipment
Approximately ₹72 crore is allocated towards procurement of plant and machinery equipment at existing manufacturing facilities in Goa and Visakhapatnam.
Additional manufacturing capacity and equipment can support the company's ability to scale production as demand for Truenat instruments and test kits increases.
Automation
Molbio also has an ₹80.8 crore internal or allocated automation initiative aimed at enhancing assembly-line automation across Goa and Visakhapatnam.
The objective is to reduce dependence on manual processes, minimise wastage and improve manufacturing efficiency. Greater automation can potentially support gross margins as production volumes increase.
The automation allocation is described as an internal or allocated initiative and therefore should not be viewed as an additional ₹80.8 crore of fresh IPO proceeds on top of the ₹200 crore issue. The stated fresh-issue deployment includes R&D infrastructure, plant and machinery and general corporate purposes.
General Corporate Purposes
The balance of the fresh issue proceeds will be used for general corporate purposes.
Overall, the use of funds indicates that Molbio is directing new capital towards technology, manufacturing scale and operational efficiency, rather than using the IPO primarily for debt reduction.
Molbio Diagnostics operates in the point-of-care molecular diagnostics market, where testing is performed closer to the patient instead of relying entirely on centralised laboratories.
The company's business model has two important components.
First, it sells Truenat diagnostic equipment. Second, and more importantly from a recurring revenue perspective, it sells the consumable test kits used with the equipment.
This creates a business model that can be compared conceptually with a razor-and-blade model. The initial diagnostic instrument creates an installed base, while recurring test-kit consumption can generate revenue as the equipment is used repeatedly.
This model can provide greater revenue visibility when installed instruments continue to generate demand for consumables.
Molbio's diagnostic portfolio covers infectious diseases such as:
-
Tuberculosis
-
Hepatitis
-
Dengue
-
COVID-19
The company also operates in testing areas related to non-communicable disease indicators.
As its installed base expands, the potential recurring demand for assays and consumables becomes an important part of the company's growth opportunity.
The Truenat platform is the central technology behind Molbio Diagnostics' business.
Truenat is a portable, battery-operated real-time PCR platform designed to provide molecular diagnostic results at the point of care. According to the provided company information, the platform has received endorsement from the World Health Organization.
Traditional molecular diagnostic testing can require sophisticated laboratories, specialised infrastructure and reliable electricity. A portable platform can potentially overcome some of these constraints.
Truenat is designed to provide results in under 60 minutes, making it suitable for decentralised testing environments.
Its battery-powered design is particularly relevant in remote locations and healthcare settings where uninterrupted electricity or advanced laboratory infrastructure may not be available.
Why Point-of-Care Molecular Diagnostics Matter
Point-of-care molecular diagnostics can help move testing closer to patients.
This can be particularly useful for:
-
Remote healthcare centres
-
Resource-constrained regions
-
Public health programmes
-
Disease surveillance
-
Outbreak response
-
Community-level screening
-
Healthcare facilities without sophisticated central laboratories
The ability to combine molecular testing with portability is one of the key differentiators of Molbio's business.
Molbio Diagnostics has established a manufacturing footprint across India.
The company operates six manufacturing plants across Goa, Visakhapatnam, Bengaluru and Pune.
The manufacturing network supports production of diagnostic equipment and consumables while providing a base for scaling the Truenat ecosystem.
Beyond India, Molbio has a commercial presence in more than 90 countries.
This international footprint provides access to a broader addressable market and reduces the company's dependence on a single geography from a long-term growth perspective.
International expansion can also increase the utilisation of the company's technology platform, particularly in countries where decentralised diagnostics can address healthcare infrastructure constraints.
Molbio Diagnostics operates in a specialised segment where technological capabilities, regulatory approvals, manufacturing expertise and customer relationships can create meaningful entry barriers.
1. Proprietary Technology
The Truenat platform represents an internally developed molecular diagnostic technology ecosystem. Proprietary technology can create differentiation compared with companies that primarily operate laboratory networks or distribute third-party diagnostic products.
2. WHO-Endorsed Platform
The WHO endorsement of Truenat strengthens its credibility for applications in public health and international healthcare programmes.
This is particularly relevant for infectious disease testing, where international organisations and government health programmes can represent significant customers.
3. Recurring Consumables
The installed base of Truenat instruments creates an opportunity for recurring test-kit revenue.
Once an instrument is deployed, continued testing requires compatible consumables. This can potentially increase customer retention and recurring revenue characteristics.
4. Global Distribution
Presence in more than 90 countries gives Molbio an established international commercial network. Expansion across emerging healthcare markets could provide additional growth opportunities.
5. Manufacturing Capabilities
Six manufacturing facilities across key Indian locations provide the company with an established production base and scope to increase capacity through additional equipment and automation.
Molbio Diagnostics has reported consistent revenue growth between FY24 and FY26.
Revenue from operations increased from ₹841.10 crore in FY24 to ₹1,027.94 crore in FY25 and ₹1,445 crore in FY26.
This represents approximately 31.5% revenue CAGR between FY24 and FY26.
Profitability has also remained positive, although profit growth has been considerably slower than revenue growth.
PAT increased from ₹136.20 crore in FY24 to ₹138.58 crore in FY25 and ₹164.14 crore in FY26, translating into an approximate 9.7% CAGR over the two-year period.
Molbio Diagnostics Financial Snapshot
| Financial Metric |
FY24 → FY26 |
| Revenue from operations |
₹841.10 crore → ₹1,445 crore |
| PAT |
₹136.20 crore → ₹164.14 crore |
| Revenue CAGR |
Approximately 31.5% |
| PAT CAGR |
Approximately 9.7% |
The financial performance shows strong expansion in revenue, while the slower growth in profitability highlights an important area for investors to assess. The following sections examine the company's revenue growth and profit growth separately.
Revenue Growth Shows Strong Business Expansion
Molbio's revenue growth is one of the strongest aspects of its financial profile.
Revenue increased by nearly ₹604 crore between FY24 and FY26, rising from ₹841.10 crore to ₹1,445 crore.
The approximate 31.5% CAGR indicates that the company has expanded considerably over the period.
The growth opportunity is linked to increasing adoption of decentralised molecular diagnostics, expansion of the Truenat installed base, recurring demand for test kits and international market expansion.
However, revenue growth should be evaluated alongside profit growth because the two have not expanded at the same pace.
Profit Growth Remains More Moderate
PAT increased from ₹136.20 crore in FY24 to ₹164.14 crore in FY26.
Although the company remained profitable, the approximately 9.7% PAT CAGR is substantially below the revenue CAGR of around 31.5%.
This difference is important for investors because strong revenue growth does not automatically translate into proportionately higher earnings.
Future operating leverage, manufacturing automation, product mix and higher utilisation of the Truenat ecosystem will therefore be important factors in determining whether profit growth can accelerate.
At the upper price band of ₹807 per share, Molbio Diagnostics commands an estimated market capitalisation of approximately ₹9,300 crore.
Based on FY26 earnings, the IPO valuation translates into approximately:
-
P/E ratio: 56.5x
-
EV/EBITDA: 28.5x
A P/E multiple of around 56.5x indicates that investors are being asked to pay a substantial premium for Molbio's earnings.
The valuation therefore depends not only on the company's existing profitability but also on its ability to sustain high revenue growth, expand margins and monetise its global point-of-care diagnostics opportunity.
The company's stated peer group includes listed diagnostics businesses such as Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic.
The trailing P/E average of the peer group is approximately 64.9x.
At around 56.5x FY26 earnings, Molbio's implied P/E is below this stated peer average.
However, direct comparison has limitations because Molbio's business model differs materially from traditional diagnostic chains.
Traditional diagnostic companies generally operate laboratory networks and collection centres, whereas Molbio focuses on molecular diagnostic technology, portable testing platforms and consumables.
Valuation Snapshot
| Valuation Metric |
Molbio Diagnostics |
| Market capitalisation at ₹807 |
Approximately ₹9,300 crore |
| FY26 P/E |
Approximately 56.5x |
| FY26 EV/EBITDA |
Approximately 28.5x |
| Peer trailing P/E average |
Approximately 64.9x |
Is Molbio Diagnostics IPO Valuation Expensive?
The valuation can be described as premium, but it is not straightforward to classify it solely against traditional diagnostic companies.
At approximately 56.5x FY26 earnings, Molbio trades at a high absolute earnings multiple. At the same time, the stated peer average of approximately 64.9x indicates that its P/E is below the selected diagnostic peer group.
The key difference is the nature of the business.
Molbio has proprietary molecular diagnostics technology, a global presence, a recurring consumables component and exposure to decentralised healthcare infrastructure. These characteristics can justify a different valuation framework from a conventional pathology-chain business.
The investment case therefore depends heavily on whether Molbio can convert its revenue growth and technology advantage into stronger earnings growth over the coming years.
The investment case also comes with meaningful risks. Investors should evaluate these risks alongside the company's growth opportunities.
1. High Customer Concentration Is a Major Risk
More than 80% of finished goods revenue is derived from government health agencies, international NGOs and public aid programmes, according to the provided company data.
This concentration creates a significant dependency on institutional and public-sector demand.
Government procurement can be influenced by:
A delay in tender awards or a reduction in government healthcare spending could affect revenue visibility.
This is particularly important because public health programmes can involve large but irregular orders.
2. Large OFS Component Limits Fresh Capital
The IPO has a ₹739.70 crore OFS compared with a ₹200 crore fresh issue.
As a result, a large portion of the total IPO proceeds goes to existing shareholders rather than the company.
For investors, the distinction is important because only the fresh issue directly adds new capital to Molbio's balance sheet for expansion and corporate purposes.
The large OFS also means the IPO provides existing shareholders and early investors with an opportunity to monetise part of their holdings.
3. Premium Valuation Creates Execution Risk
At approximately 56.5x FY26 earnings, Molbio is valued at a premium in absolute terms.
Even though this is below the stated peer average of 64.9x, the company still needs to deliver sustained growth to justify the valuation.
If revenue growth slows, margins decline or earnings fail to scale with the company's expansion, the high earnings multiple could become a source of downside risk.
4. Dependence on Healthcare Programmes
Molbio's exposure to tuberculosis programmes and other public health initiatives provides a large addressable market, but it also creates dependency on institutional procurement.
Changes in disease-control priorities, government funding or international healthcare programmes could affect demand.
5. Technology and Regulatory Risk
Diagnostics is a highly regulated and technology-driven industry.
Maintaining product quality, regulatory compliance and clinical credibility across multiple countries is essential.
As Molbio expands its product portfolio and international operations, it may need to navigate different regulatory frameworks and healthcare procurement requirements.
The Molbio Diagnostics IPO GMP was reported around ₹125 to ₹132 per share as the issue opened.
Based on the upper price band of ₹807, this implied a potential premium of approximately 15% to 16% over the issue price.
However, the grey market premium is not an official indicator of listing price and can change rapidly based on market sentiment, IPO subscription levels and broader market conditions.
The GMP had previously reached around ₹220 per share before cooling, demonstrating considerable volatility ahead of the issue.
Investors should therefore avoid treating GMP as a guaranteed listing gain indicator.
The Molbio Diagnostics IPO differs based on the investor's time horizon. The IPO may offer a different proposition to investors looking for short-term listing gains compared with those evaluating the company for long-term investment.
For Listing Gain Seekers
The reported GMP of around ₹125 to ₹132 per share when the IPO opened indicated the possibility of a moderate listing premium over the upper price band of ₹807.
However, GMP is unofficial and can change before listing. It had previously reached around ₹220 before cooling, so investors should treat GMP as an indication of market sentiment rather than a guaranteed return.
For Long-Term Investors
For long-term investors, the initial listing price is less important than how the company performs after listing. Molbio's ability to execute its growth strategy and translate business expansion into sustainable earnings will be central to its long-term investment case.
The company is therefore more suited to investors who are willing to evaluate its performance over several years rather than focus only on the listing-day movement.
Overall View
-
Listing gains: Potentially moderate based on the reported GMP, but subject to market volatility.
-
Long-term investment: Depends on sustained execution and earnings growth.
-
Investment approach: Investors should assess the business based on its post-listing performance rather than short-term price movements.
Overall, Molbio Diagnostics presents a different proposition for short-term and long-term investors, making the investment horizon an important consideration when evaluating the IPO.
The IPO analysis should not end on the listing date. Investors evaluating the company after listing should monitor several operating indicators.
1. Revenue Growth
The company needs to maintain a healthy growth rate to support its premium valuation.
2. PAT Growth
The gap between revenue CAGR and PAT CAGR is an important area to watch. Sustained improvement in earnings growth would strengthen the investment thesis.
3. Truenat Installed Base
Growth in the number of Truenat systems deployed can indicate future potential for recurring consumables revenue.
4. Consumables Revenue
The recurring test-kit business is strategically important because it can provide repeat revenue from existing instruments.
5. International Expansion
Growth across the more than 90 countries where Molbio has a commercial presence can broaden its revenue base.
6. Customer Concentration
A reduction in dependence on government agencies, NGOs and public aid programmes would improve customer diversification.
7. Manufacturing Automation
Automation across Goa and Visakhapatnam could improve production efficiency, reduce wastage and potentially support margins.
8. R&D Investment
Continued investment in the Centre of Excellence and R&D infrastructure will be important for product innovation and expansion into additional diagnostic applications.
Molbio Diagnostics has several factors that could support its growth, alongside risks that investors should evaluate before applying. Below are the key positives and concerns:
Key Positives
-
Proprietary Truenat molecular diagnostics platform
-
WHO-endorsed technology
-
Portable and battery-operated testing system
-
Results available in under 60 minutes
-
Recurring consumables-based business model
-
Presence across more than 90 countries
-
Six manufacturing facilities in India
-
Strong FY24 to FY26 revenue CAGR of approximately 31.5%
-
₹281.5 crore anchor investment from 33 investors
-
Domestic mutual funds accounted for 67.5% of anchor allocation
-
Fresh issue proceeds directed towards R&D, manufacturing and infrastructure
Key Concerns
-
More than 80% of finished goods revenue comes from government agencies, NGOs and public aid programmes
-
Large OFS of ₹739.70 crore
-
Premium valuation at approximately 56.5x FY26 P/E
-
PAT growth has been slower than revenue growth
-
Dependence on government and institutional procurement
-
Grey market premium has shown significant volatility
-
International expansion involves regulatory and execution risks
The Molbio Diagnostics IPO 2026 offers exposure to a specialised point-of-care molecular diagnostics business with proprietary technology, recurring consumables revenue and a growing international footprint.
The strongest elements of the investment case are the Truenat platform, WHO endorsement, global presence, manufacturing infrastructure and strong revenue growth. The ₹200 crore fresh issue is also directed towards R&D, manufacturing equipment and infrastructure, which can support future capacity and product development.
At the same time, the IPO is not without concerns. Customer concentration is high, the issue is dominated by an OFS, PAT growth has lagged revenue growth and the valuation remains premium.
For listing-focused investors, the reported GMP suggests potential for a moderate listing premium, but this should not be treated as a guaranteed return.
For long-term investors, Molbio offers a differentiated healthcare technology proposition, but the investment case depends on sustained revenue growth, better earnings conversion, successful international expansion and continued adoption of the Truenat ecosystem.
Overall, the Molbio Diagnostics IPO Analysis points to a business with strong structural opportunities but a valuation and customer concentration profile that requires careful evaluation. Investors should assess the IPO based on the company's ability to convert its technological advantage and growing installed base into sustainable long-term earnings.
Want to compare Molbio Diagnostics with other mainboard issues on pricing, issue size, valuation, and listing trends? Use the IPO dashboard to track current and upcoming offerings.
1. What is the Molbio Diagnostics IPO?
Molbio Diagnostics IPO is a ₹939.70 crore mainboard public issue consisting of a ₹200 crore fresh issue and a ₹739.70 crore Offer for Sale.
2. Is Molbio Diagnostics profitable?
Yes. Molbio Diagnostics reported PAT of ₹164.14 crore in FY26, compared with ₹138.58 crore in FY25 and ₹136.20 crore in FY24.
3. What is Molbio Diagnostics' revenue?
Revenue from operations increased to ₹1,445 crore in FY26 from ₹1,027.94 crore in FY25 and ₹841.10 crore in FY24.
4. What is the valuation of Molbio Diagnostics IPO?
At the upper price band of ₹807, the company has an estimated market capitalisation of approximately ₹9,300 crore. Its FY26 P/E is approximately 56.5x and EV/EBITDA is approximately 28.5x.
5. What are the main risks of Molbio Diagnostics IPO?
The major risks include high customer concentration, dependence on government and institutional procurement, the large OFS component, premium valuation, slower PAT growth relative to revenue growth and regulatory and execution risks associated with international expansion.